Moreover, multiple targets notorious for their association with other disease conditions were identified in our studies, such as TSLP, IL7R, PDPN, sST2, IL-11, SAA3, C3, and CC and CXC chemokines, which may serve as novel targets for RDEB therapeutic development. The gene discussed is CXCR1; the disease is recessive dystrophic epidermolysis bullosa.